BioStar Capital’s investment strategy is driven by a deep-seated commitment to improving patient lives and maximizing returns for our investors.
Opportunities are then assessed by BioStar Capital’s leadership team and Medical Venture Partners (MVPs), who are experienced medical practitioners, for commercial relevance, potential buyers, capital needs, IP, clinical impact, and value-add opportunities.
Investment opportunities come through BioStar Capital’s healthcare connections, many as a direct result of our reputation, track record, access to patients and clinical trials at leading research centers, and assistance in securing FDA approvals.
Our team of experts provides additional value to our portfolio companies by supporting the achievement of both clinical and commercial objectives, ultimately guiding them towards a successful exit.
Given our deep clinical expertise, we focus on innovation in Medtech that addresses unmet patient
needs with an emphasis on Cardiovascular and Orthopedics, both major billion-dollar markets:
“Smart” devices & robotics
Minimally invasive solutions